Wells Fargo & Company Initiates Coverage on PerkinElmer, Inc. (PKI)

Analysts at Wells Fargo & Company began coverage on shares of PerkinElmer, Inc. (NYSE:PKI) in a research note issued to investors on Thursday, July 13th, Marketbeat Ratings reports. The firm set a “market perform” rating and a $72.00 price target on the medical research company’s stock. Wells Fargo & Company’s target price would suggest a potential upside of 12.62% from the stock’s current price.

A number of other brokerages have also issued reports on PKI. Evercore ISI restated an “in-line” rating and set a $68.00 target price (up previously from $62.50) on shares of PerkinElmer in a research report on Thursday, June 22nd. Barclays PLC set a $55.00 price target on shares of PerkinElmer and gave the stock a “sell” rating in a report on Saturday, May 6th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $65.00 price target on shares of PerkinElmer in a report on Friday, May 5th. Jefferies Group LLC reaffirmed a “hold” rating and set a $49.00 price target on shares of PerkinElmer in a report on Friday, May 5th. Finally, Janney Montgomery Scott raised shares of PerkinElmer from a “neutral” rating to a “buy” rating in a report on Monday, March 27th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. PerkinElmer has an average rating of “Hold” and a consensus price target of $67.00.

PerkinElmer (PKI) traded up 1.56% during midday trading on Thursday, hitting $63.93. 497,434 shares of the company traded hands. The stock’s 50-day moving average price is $67.48 and its 200 day moving average price is $60.66. PerkinElmer has a 12-month low of $45.35 and a 12-month high of $70.16. The company has a market capitalization of $7.05 billion, a price-to-earnings ratio of 19.28 and a beta of 0.75.

PerkinElmer (NYSE:PKI) last announced its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.67. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The firm had revenue of $547 million for the quarter, compared to analyst estimates of $554.14 million. During the same quarter in the prior year, the business posted $0.67 EPS. The business’s revenue was up 2.0% compared to the same quarter last year. On average, equities analysts forecast that PerkinElmer will post $2.89 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Wells Fargo & Company Initiates Coverage on PerkinElmer, Inc. (PKI)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.com-unik.info/2017/08/11/perkinelmer-inc-pki-coverage-initiated-at-wells-fargo-company-updated-updated-updated.html.

In related news, Director Peter Barrett sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $63.22, for a total value of $632,200.00. Following the completion of the transaction, the director now owns 29,200 shares of the company’s stock, valued at approximately $1,846,024. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Patrick J. Sullivan sold 6,628 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $62.59, for a total transaction of $414,846.52. Following the completion of the transaction, the director now owns 42,951 shares of the company’s stock, valued at $2,688,303.09. The disclosure for this sale can be found here. In the last three months, insiders sold 20,986 shares of company stock valued at $1,330,317. 2.20% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new position in shares of PerkinElmer during the fourth quarter valued at about $988,000. Dimensional Fund Advisors LP boosted its position in shares of PerkinElmer by 8.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 772,837 shares of the medical research company’s stock valued at $40,304,000 after buying an additional 59,736 shares during the period. Federated Investors Inc. PA boosted its position in shares of PerkinElmer by 158.4% in the fourth quarter. Federated Investors Inc. PA now owns 2,997 shares of the medical research company’s stock valued at $156,000 after buying an additional 1,837 shares during the period. Norges Bank acquired a new position in shares of PerkinElmer during the fourth quarter valued at about $46,002,000. Finally, Kentucky Retirement Systems acquired a new position in shares of PerkinElmer during the fourth quarter valued at about $415,000. Hedge funds and other institutional investors own 92.77% of the company’s stock.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

What are top analysts saying about PerkinElmer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PerkinElmer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit